Chiara Lambertini
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
Journal: Journal of the National Cancer Institute
Published: March 18, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: January 15, 2025
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Journal: Future oncology (London, England)
Published: November 16, 2022
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 23, 2022
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 28, 2022
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 22, 2022
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
Journal: Breast cancer research : BCR
Published: April 22, 2022
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.
Journal: NPJ breast cancer
Published: March 10, 2022
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Journal: The Lancet. Oncology
Published: March 10, 2020
Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Journal: Regulatory peptides
Published: April 23, 2013
Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system.
Journal: Journal of clinical pathology
Published: November 06, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026